INSYS Therapeutics, Inc. INSY was a big mover last session with its shares rising nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost over 42% since May 1.
This specialty pharmaceutical company has seen one negative estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's rally can last.
INSYS Therapeutics currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Investors interested in the Medical Products industry may consider better-ranked stocks like Cardica Inc. CRDC, ICU Medical, Inc. ICUI and Mead Johnson Nutrition Company MJN. All three stocks bear a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
This specialty pharmaceutical company has seen one negative estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's rally can last.
INSYS Therapeutics currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Investors interested in the Medical Products industry may consider better-ranked stocks like Cardica Inc. CRDC, ICU Medical, Inc. ICUI and Mead Johnson Nutrition Company MJN. All three stocks bear a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CARDICA INC CRDC: Free Stock Analysis Report
ICU MEDICAL INC ICUI: Free Stock Analysis Report
INSYS THERAP INSY: Free Stock Analysis Report
MEAD JOHNSON NU MJN: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
